Prokarium
Microbial immunotherapy platform built on a proprietary bacterial strain (ZH9) for solid tumour treatments
Highlights
- New on EvolcAdded 2026-10-28
About Prokarium
Prokarium develops microbial immunotherapies for solid tumours. Its foundational technology uses a proprietary bacterial strain, ZH9, as a chassis that targets tumours, overcomes the suppressive tumour microenvironment and can deliver diverse cargo.
The company's pipeline includes ZH9 in non-muscle invasive bladder cancer, a Phase 1 programme started in the US, and ZH9 in muscle invasive bladder cancer in combination with checkpoint inhibitors. It also lists IO Prime, an oral immune fitness agent, and the Living Cures Platform, a discovery cargo-delivery immunotherapy platform.
Prokarium was founded in 2007 and is headquartered in London, with its office at the London Bioscience Innovation Centre. The company describes itself as clinical-stage and reported interim Phase 1/1b PARADIGM-1 data for ZH9 in May 2026. Its leadership includes a CEO appointed in November 2025.
Product: ZH9 bacterial immunotherapy for solid tumours, with pipeline programmes IO Prime and the Living Cures Platform
Jobs at Prokarium
More biotech & pharma companies
Protein Stable
Microplate instruments for protein characterisation used by scientists in academia and biotechnologyNew on EvolcProveca
Develops and licenses medicines for children with unmet needs in neurology and cardiologyNew on EvolcPsivac
Develops oncolytic adenovirus therapies for cancer patients, targeting solid tumoursNew on EvolcQuantumdx Group
Point-of-care molecular diagnostic platforms and assays for clinicians and healthcare providersNew on EvolcReach Separations
Chromatography analysis and purification services for pharmaceutical, agrochemical and fine chemical companiesNew on EvolcSalary transparentRedx Pharma
Clinical-stage biotech developing small-molecule anti-fibrotic drugs, led by a ROCK inhibitor for Crohn's diseaseNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Framer